Real World Evidence on the Use of Medical Cannabis in Pediatrics

University of Manitoba500 enrolled

Overview

CAN-RWE is an observational study that is following 500 children who have authorizations for medical cannabis for two years from across Canada.

Pediatric patients (3 to 17 years) using medical cannabis (MC) for pain, sleep, mood, behaviour, seizures, treatment of cancer, or to manage symptoms related to cancer or cancer-treatment are eligible to join this 24-month study if they have a valid MC authorization. Following screening, eligible participants will be contacted by the study coordinator. Following informed consent, study participants will record complete outcome measures on pain, sleep, mood (anxiety, depression and positive affect), behaviour, as well as report their cannabis use and indication-specific outcomes as applicable at 3, 6, 12, and 18 weeks, as well as 6, 12, 18 and 24-months.

Study Type

OBSERVATIONAL

Enrollment

500

Conditions

Cancer Epilepsy Neurodevelopmental Disorders

Interventions

Medical CannabisDRUG

Any cannabis product that is available to participants through the Medical Cannabis Access Program is eligible to be included in this study.

Eligibility

Sex: ALLMin age: 3 YearsMax age: 17 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 3 to 17 years * have a medical document provided by a prescribing health care practitioner (i.e. physician, nurse practitioner, etc.) for the use of medical cannabis * medical cannabis is authorized for pain, sleep, mood, behaviour, seizures, cancer or cancer-treatment related symptom management * ability to respond to electronic questionnaires in English Exclusion Criteria: * individuals using cannabis for medical purposes without a medical cannabis authorization from a health care provider * those only using cannabis recreationally

Locations (1)

U Manitoba

Winnipeg, Manitoba, Canada

RECRUITING

Outcomes

Primary Outcomes

Patterns of cannabis use (caregiver-reported)

Describe patterns of cannabis use are described using a standard data collection form including dose and product type completed by caregivers at baseline, 3, 6, 12, and 18-weeks and 6, 12, 18 and 24-months